SEC Form 4 · accession 0001197350-26-000010
Mirum Pharmaceuticals, Inc. · MIRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — CHIEF FINANCIAL OFFICER
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001759425
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 11, 2026 | M | 18,333 | — | A | 54,688 | D | |
| Common Stock | Sep 14, 2026 | S | 9,943 | $98.37 | D | 44,745 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Sep 11, 2026 | M | 18,333 | D | — | — | Common Stock | 18,333 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
- F2Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- F3The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.